Xiangyang Xu

Title: Innovations of Xiangyang Xu in Pharmaceutical Development

Introduction

Xiangyang Xu is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of modified recombinant human endostatin. His work focuses on enhancing the efficacy and stability of therapeutic agents used in cancer treatment.

Latest Patents

Xiangyang Xu holds a patent for a modified recombinant human endostatin, which is characterized by the structure CHO—(CHCHO)—CHCHCH—NH-Endostar. The average molecular weight of CHO—(CHCHO)—CHCHCH— is between 20-40 kD. This innovative formulation enhances stability in vivo, improves blood drug concentration, and prolongs the half-life of the drug. It also significantly increases the activity of inhibiting endothelial cell proliferation, thereby reducing the required drug dosage and administration frequency. The patent further outlines its application in preparing anti-tumor pharmaceutical compositions.

Career Highlights

Throughout his career, Xiangyang Xu has worked with prominent companies in the pharmaceutical industry. He has been associated with Jiangsu Simcere Pharmaceutical R&D Co., Ltd and Shandong Xiansheng Maidejin Biological Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Xiangyang Xu has collaborated with notable professionals in his field, including Hong Tian and Wenbing Yao. These collaborations have likely enriched his research and development efforts, leading to advancements in pharmaceutical technologies.

Conclusion

Xiangyang Xu's contributions to the field of pharmaceuticals, particularly through his patented innovations, demonstrate his commitment to improving cancer treatment options. His work continues to influence the development of effective therapeutic agents.